The upgrade got my attention, but positive-looking charts pushed me over the edge.
There's an undercurrent that will grow over time, basically what tailwinds from the pandemic will stay with us after the pandemic's over.
The name appears bearish and risky right now.
The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.
The migraine drugmaker has been sending weak technical signals for a few months now.
Volume has picked up dramatically since a selloff in the online health services provider began, and it could get worse.
I hate chasing a stock but it looks like I need to get with the program.
Since we don't have a breakout, I would stay with a half-size approach on any trade here.
Let's see if it's time to jump back on the bike.
At current levels BMY is sort-of in no man's land - not bullish and not bearish.